Shubham Pant: Celebrating RASolute302 Results of Daraxonrasib in Pancreatic Cancer
Shubham Pant/LinkedIn

Shubham Pant: Celebrating RASolute302 Results of Daraxonrasib in Pancreatic Cancer

Shubham Pant, Professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at MD Anderson Cancer Center, shared a post on LinkedIn:

“Celebrating the exciting results of the RASolute302 study of Daraxonrasib in pancreatic cancer with the incredible research staff UT MD Anderson who work behind the scenes to make it all possible.

Clinical trials are never the work of one person. While Investigators may present the data and publish the results, none of this happens without the dedication and hard work of these unsung heroes: research coordinators, research nurses, data managers, regulatory specialists, budget and finance teams, who work tirelessly every day to bring promising therapies to our patients.

To our entire clinical trial team: thank you for being our partners in Making Cancer History”

Shubham Pant

Other articles featuring Shubham Pant on OncoDaily.